Stanford (Calif.) Cancer Institute has tapped Vivek Subbiah, MD, as inaugural associate director for drug development and precision oncology.
Dr. Subbiah was also appointed as executive medical director for cancer novel therapies and clinical trial network development at Stanford (Calif.) Health Care, according to a Feb. 27 news release.
He previously served as chief of early-phase drug development at Nashville, Tenn.-based Sarah Cannon Research Institute, and as executive director of medical oncology research and the clinical medical director of the phase 1 program at Houston-based University of Texas MD Anderson Cancer Center.
Leave a Reply